IRVINE, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical…
AUSTIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…